This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Mycoplasma Detection Systems Market

Mycoplasma Detection Systems Market

Mycoplasma Detection Systems Market by Product Type (Kits and Reagents, Services, Systems) by Technique (PCR, ELISA, Direct & Indirect Assay), by End User (Pharmaceutical & Biopharmaceutical Companies, Research Laboratories, by Region - Global Insights 2022-2032

Mycoplasma Detection Systems Market
FACT446MR
  • Apr-2022
  • List of Tables : 41
  • List of Figures : 95
  • 170 Pages
  • Healthcare

Mycoplasma Detection Systems Industry Overview (2022-2032)

The global mycoplasma detection systems market is likely to be valued at US$ 600 Million in FY 2022, up from US$ 560 Million in 2021. During the past year, the industry registered a Y-o-Y increase worth 7.1%. From 2022 to 2032, mycoplasma detection systems sales are poised to flourish at a CAGR of 9.6% to reach a value of US$ 1.5 Billion by the end of 2032.

Report Attributes

Details

Anticipated Base Year Value (2021)

US$ 560 Million

Expected Market Value (2022)

US$ 600 Million

Projected Forecast Value (2032)

US$ 1.5 Billion

Global Growth Rate (2022-2032)

9.6% CAGR

Growth Rate of the U.S Market (2022-2032)

7.1% CAGR

Expected Market Value of China (2032)

US$ 3.1 Billion

U.K Market Expansion Rate (2022-2032)

12.8% CAGR

Key Companies Profiled

  • Agilent Technologies
  • Abbott
  • Eurofins Scientific
  • Charles River Laboratories International Inc.
  • F. Hoffmann-La Roche Ltd
  • Lonza Group
  • PromoCell GmbH
  • Merck KGaA
  • Sartorius AG
  • Thermo Fisher Scientific Inc.

Demand for mycoplasma detection systems equipment will continue to thrive, with a documented CAGR of 9.6% during the 2015-2021 historical period of assessment, while demand for mycoplasma detection systems in biochemical & pharmaceutical sector proliferated at a rate of 13.3% during the same time period. The APAC will dominate the global market, registering a growth opportunity worth US$ 3.1 Billion from 2022 to 2032.

Avail customized purchase options for your needs

2015 to 2021 Mycoplasma Detection Systems Market Revenue Analysis vs. Market Outlook 2022-2032

Fact.MR has predicted the mycoplasma detection systems market to surge at a 9.6% CAGR between 2022 and 2032 in comparison to the 9.3% CAGR throughout the historic period. The increasing emphasis on mycoplasma testing after the occurrence of COVID-19 by the global pharmaceutical companies & research companies boosts the demand for the mycoplasma detection systems kits and reagents across the globe.

Manufacturers are making hefty investments to develop the easy-to-use kits equipment and reduce the cost of systems & services for the detection of bacteria which are complex to detect from microscope.

Key Drivers Stimulating Mycoplasma detection systems Industry Expansion

Mounting R&D Stashes in the Field of Life Sciences Expands the Consumer Base for Mycoplasma Testing Products

Mycoplasma infection is tough to investigate through microscope and needs specific tests to be detected. Infection can have a critical consequence on experimental work based on the species present. This will result in cross contamination of cell cultures and push the growth rate for mycoplasma testing.

Key bio pharma corporations working in the market are creating innumerable strategic investments such as instigating innovative products, advancing research, and development, and technological innovations, which are bourgeoning popularity in the mycoplasma testing market and multiply the customer base to survive in a competitive business environment.

The demand for mycoplasma testing equipment is predicted to upsurge in near future. Enormous pool of opportunities in the life sciences segment is a principal factor propelling the mycoplasma kits industry.

An Adaptive Approach to Modern-day Research Needs

Key Challenges to Mycoplasma Detection Systems Industry Expansion

Shortage of Skilled Lab Technicians to Impact Testing Efficiency

Fact.MR’s recently published analysis report summarizes that the unavailability of trained/skilled molecular biologists is likely to impede the market growth over the projection period. Mycoplasma testing needs certain specialized skills perceived in professional from life sciences, pharmaceutical, electronics, and software industries. The deficiency of trained personnel proficient of conducting molecular biology experiments and interpreting the results is a foremost limitation of testing and containment of COVID-19 in emerging nations.

Moreover, high cost of instruments and long and laborious detection procedure are likely to restrict the mycoplasma testing in clinical market development in the conjecture period.

Region-wise Analysis

How Opportunistic are Growth Prospects across North America?

Innovation in Pharmaceutical and Biotechnology Industry Bolsters the Development of Easy-to-Use Kits for Detection

In terms of market contribution, North America captures a dominant share of nearly 32% in the mycoplasma testing market and is likely to maintain its stronghold in the upcoming years.

Based on Fact.MR’s projections, this region is anticipated to expand its market share in the future, owing to its engrained healthcare industry and the mounting occurrence of chronic diseases in the region.

Several factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region.

Why is Mycoplasma detection systems Providers Venturing into the Asia Pacific?

Soaring Emphasis on Life Sciences Research has propelled Market Growth

Asia Pacific is witnessing an incremental growth in the cell culture contamination and is the fastest growing market, thereby acting as a prominent driving factor for mycoplasma testing in clinical market. Along with this, scientists and researchers are constantly working on developing easy to use test kits and reagents for quick detection of micro bacteria. Snowballing Life sciences research are likely to create a plethora of growth opportunities in the region.

Mycoplasma testing in clinical marketplace contains aspects such as strategic ingenuities by key players which will impact in launching new products by the manufacturers in the developing countries like China, India & Japan. This aspect augments the demand for fast and accurate testing and mycoplasma testing systems in clinical market. Fact.MR forecasts the APAC market valuation for mycoplasma detection systems to reach around US$ 900 Million by the end of the 2022-2032 forecast period.

Country-wise Value CAGRs for Mycoplasma Detection Systems (2022-2032)

U.S

7.1%

U.K

12.8%

China

14.3%

Japan

13.1%

South Korea

13.2%

Mycoplasma Detection Systems Market forecast analysis by Fact.MR

Category-wise Insights

Which Product Type is Most Preferred in the Mycoplasma detection systems Market?

Increasing Biopharmaceutical Production is set to Boost Demand for Mycoplasma detection systems Devices to Ensure Product Safety

Mycoplasma detection systems is gaining significant traction in the biopharmaceuticals industry. Biopharmaceuticals represent around one-fourth share of total pharmaceutical industry revenue generation which is growing year on year by a substantial rate.

The superior efficacy of biopharmaceuticals in treating chronic diseases is making them the choice of treatment which in turn is increasing biopharmaceutical production. Mycoplasma is the most common contaminant in the biopharmaceuticals industry; therefore, mycoplasma detection systems devices are gaining significant adoption to ensure biopharmaceuticals product safety. With constantly evolving contamination detection techniques and the growing adoption of biopharmaceuticals in healthcare, this is expected to create several opportunities for mycoplasma detection systems market growth.

By Technique, which Mycoplasma detection systems is expected to Dominate?

Higher Operational Efficiency with PCR based Mycoplasma detection systems Technique Compare to Traditional Detection

The PCR based technique for mycoplasma detection systems is alternative to costly, time-consuming culture-based tests which often done externally by contract labs and it can take up to 28 days. Mycoplasma detection systems is used at different stages of manufacturing, to eliminate the faulty batch and not the entire set of production batches.

The traditional detection of mycoplasma contamination using culture-based test often requires close to 4 weeks whereas mycoplasma testing using advanced methods such as kits and systems often provides instant results with a minimum margin of error. For example, MycoSEQ assay (By Thermo Fisher Scientific) can identify more than 90 mycoplasma species in under five hours, with well-documented specificity and sensitivity.

Interested to Procure The Data

Competitive Landscape

Prominent Mycoplasma detection systems providers are reliant on partnerships, collaborations, acquisitions, and new software launches so as to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.

  • In June 2021, Agilent Technologies Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm's portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent's portfolio of automated pathology staining solutions.
  • In Nov 2021, Merck KGaA, a leading science and technology company, announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry to help solve the toughest problems in life science.

Key Segments Covered in the Mycoplasma Detection Systems Industry Survey

  • Mycoplasma detection systems by Product Type

    • Mycoplasma detection systems Kits and Reagents
      • Nucleic Acid Detection Kits
      • PCR Assays
      • Elimination Kits & Reagents
      • Others
    • Mycoplasma Detection Services
    • Mycoplasma Detection Systems
      • PCR Based Systems
      • Luminescence Based Systems
  • Mycoplasma Detection Systems by Technique

    • PCR Mycoplasma detection systems
    • ELISA Mycoplasma detection systems
    • Direct & Indirect Assay Mycoplasma detection systems
    • Others
  • Mycoplasma Detection Systems by End User

    • Mycoplasma Detection Systems in Pharmaceutical & Biopharmaceutical Companies
    • Mycoplasma detection systems in Research Laboratories
    • Mycoplasma detection systems in Contract Research Organizations (CROs)
    • Mycoplasma detection systems in Academic Research Institutes
  • Mycoplasma Detection Systems by Region

    • North America Mycoplasma Detection Systems Market
    • Latin America Mycoplasma Detection Systems Market
    • Europe Mycoplasma Detection Systems Market
    • Asia Pacific Mycoplasma Detection Systems Market
    • Middle East & Africa Mycoplasma Detection Systems Market

- FAQs -

As of 2021, Fact.MR estimated the mycoplasma detection systems market to have reached US$ 560 Million
By 2022, Fact.MR expected demand for mycoplasma detection systems to reach US$ 600 Million
From 2015-2021, the Mycoplasma detection systems market grew at a 9.3% value CAGR
From 2022-2032, mycoplasma detection systems demand is likely to surge at a 9.6% CAGR
By 2032, the market for Mycoplasma detection systems is likely to be valued at US$ 1.5 Billion
By 2032, Fact.MR expects the U.S market for mycoplasma detection systems to expand at a 7.1% CAGR
China is expected to register a 14.3% CAGR with regard to the Mycoplasma detection systems industry
South Korea and Japan are expected to document CAGRs worth 13.3% and 13.1% respectively in the Mycoplasma detection systems market
Based on product, mycoplasma detection systems kits and reagents will be maximum, expanding at a 13.3% CAGR
Mycoplasma detection systems in pharmaceutical & biotechnology will remain most preferred, expanding at a CAGR of 14.1% until 2032

Need an Exclusive Report for your Unique Requirement?

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.